{"hands_on_practices": [{"introduction": "The cornerstone of managing non-invasive bladder cancer is accurate histopathologic grading, which directly influences patient prognosis and treatment. This practice challenges you to apply the World Health Organization (WHO)/International Society of Urological Pathology (ISUP) criteria to a detailed case vignette. By weighing architectural and cytologic features, you will develop the critical skill of distinguishing between diagnostically challenging categories, particularly in the presence of borderline findings that can blur the lines between low-grade and high-grade disease. [@problem_id:4465022]", "problem": "A $65$-year-old man presents with painless gross hematuria. Cystoscopy reveals a single exophytic papillary lesion measuring approximately $1.2$ cm on the lateral wall of the bladder. A Transurethral Resection of Bladder Tumor (TURBT) is performed. Histologic examination shows the following features:\n\n- Exophytic papillary architecture with delicate fibrovascular cores. The papillae demonstrate variable thickness with focal branching but overall maintain orderly, tiered nuclear alignment. The urothelium overlying the papillae is generally $6$ to $8$ cell layers thick, with an intact umbrella cell layer covering most fronds.\n- Cytologic features include mild to moderate nuclear enlargement, mild hyperchromasia, and small but identifiable nucleoli. Nuclear membranes are slightly irregular in places, but cell-to-cell cohesion is preserved. Nuclear polarity is largely maintained with nuclei oriented perpendicular to the basement membrane.\n- Mitotic activity is quantified as $3$ mitoses per $10$ High-Power Fields (HPF), predominantly in the basal to parabasal layers. A single atypical mitotic figure is identified in the upper third of one papillary frond.\n- There is focal luminal necrotic debris, but no broad zones of tumor (comedo-type) necrosis. No marked discohesion, no sheets of highly pleomorphic cells, and no obvious loss of maturation are seen. There is no flat component resembling carcinoma in situ, and the lesion is purely papillary. The lamina propria shows edema and mild inflammation without visible invasion; muscularis propria is not present in the submitted tissue.\n\nBased on the World Health Organization (WHO) and International Society of Urological Pathology (ISUP) criteria for papillary urothelial lesions, which of the following is the most appropriate diagnostic classification for this lesion?\n\nA. Urothelial papilloma\n\nB. Papillary urothelial neoplasm of low malignant potential (PUNLMP)\n\nC. Low-grade papillary urothelial carcinoma\n\nD. High-grade papillary urothelial carcinoma\n\nE. Carcinoma in situ (CIS)\n\nYour answer should be grounded in the core definitions and well-tested observational criteria endorsed by WHO/ISUP for papillary urothelial lesions, specifically considering architectural order versus disorder, degree of cytologic atypia, mitotic activity and its location, presence and pattern of necrosis, and preservation of umbrella cells and nuclear polarity. Defend the final grade assignment in the context of the borderline features described (e.g., an atypical mitotic figure and focal luminal necrotic debris).", "solution": "### Step 1: Extract Givens\n\nThe problem provides the following clinical and histopathological data for a bladder lesion in a $65$-year-old male:\n- **Clinical Presentation**: Painless gross hematuria.\n- **Cystoscopic Findings**: Single exophytic papillary lesion, approximately $1.2$ cm.\n- **Procedure**: Transurethral Resection of Bladder Tumor (TURBT).\n- **Architectural Features**:\n    - Exophytic papillary architecture with delicate fibrovascular cores.\n    - Variable papillae thickness with focal branching.\n    - Orderly, tiered nuclear alignment.\n    - Urothelial thickness of $6$ to $8$ cell layers.\n    - Intact umbrella cell layer over most fronds.\n- **Cytologic Features**:\n    - Mild to moderate nuclear enlargement.\n    - Mild hyperchromasia.\n    - Small but identifiable nucleoli.\n    - Slightly irregular nuclear membranes.\n    - Preserved cell-to-cell cohesion.\n    - Largely maintained nuclear polarity.\n- **Mitotic Activity**:\n    - $3$ mitoses per $10$ High-Power Fields (HPF), predominantly basal to parabasal.\n    - A single atypical mitotic figure in the upper third of one frond.\n- **Other Features**:\n    - Focal luminal necrotic debris.\n    - No broad zones of tumor (comedo-type) necrosis.\n    - No marked discohesion, no sheets of highly pleomorphic cells.\n    - No obvious loss of maturation.\n    - Purely papillary lesion, no flat component resembling carcinoma in situ (CIS).\n- **Staging Information**:\n    - No visible invasion of lamina propria.\n    - Muscularis propria not present in the specimen.\n\nThe question asks for the most appropriate diagnostic classification based on the World Health Organization (WHO) and International Society of Urological Pathology (ISUP) criteria.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated for validity:\n- **Scientifically Grounded**: The problem is well-grounded in the field of diagnostic surgical pathology, specifically uropathology. The terminology, clinical context, and histological descriptions are standard and factually correct. The reference to WHO/ISUP criteria confirms its basis in established, peer-reviewed classification systems.\n- **Well-Posed**: The problem is well-posed. It provides a detailed,\ninternally consistent set of observational data and asks for a diagnosis from a standard, mutually exclusive set of classifications. The level of detail allows for a reasoned, definitive conclusion.\n- **Objective**: The description is based on objective, observable microscopic features, which are the cornerstone of histopathological diagnosis. It avoids subjective or ambiguous language, instead providing quantifiable data (mitotic rate) and qualitative but standard descriptors (e.g., \"mild to moderate atypia\").\n\n### Step 3: Verdict and Action\n\nThe problem is **valid** as it is scientifically sound, well-posed, and objective. I will now proceed to a full analysis and solution.\n\n### Derivation of Solution\n\nThe diagnosis of papillary urothelial neoplasms hinges on a constellation of architectural and cytological features as defined by the WHO/ISUP classification system. The primary differential diagnosis in this case is between Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP), Low-Grade Papillary Urothelial Carcinoma, and High-Grade Papillary Urothelial Carcinoma.\n\n**Analysis of Histologic Features:**\n\n1.  **Architecture**: The architecture is described as \"exophytic papillary\" with \"orderly, tiered nuclear alignment\" and \"largely maintained nuclear polarity.\" The urothelium is thickened to $6-8$ layers. This orderly architecture suggests a low-grade process and argues strongly against high-grade carcinoma, which typically shows disordered growth, significant loss of polarity, and architectural complexity. The presence of an intact umbrella cell layer is also a feature of lower-grade lesions.\n\n2.  **Cytology**: The cytology is characterized by \"mild to moderate nuclear enlargement,\" \"mild hyperchromasia,\" \"small but identifiable nucleoli,\" and \"slightly irregular nuclear membranes.\" This degree of atypia exceeds that found in a urothelial papilloma (which is cytologically bland) and a PUNLMP (which shows only minimal atypia with smooth nuclear membranes and inconspicuous nucleoli). The description is consistent with the \"mild to moderate\" atypia definitional of low-grade papillary urothelial carcinoma. The absence of \"marked discohesion\" or \"sheets of highly pleomorphic cells\" further argues against a high-grade diagnosis.\n\n3.  **Mitotic Activity**: The mitotic rate ($3$ mitoses per $10$ HPF) and predominantly basal location are characteristic of a low-grade lesion. However, the presence of a \"single atypical mitotic figure\" is a critical finding. Atypical mitoses are a hallmark of high-grade malignancy. By strict WHO/ISUP definition, their presence, even if solitary, often precludes a diagnosis of PUNLMP. While mitotic activity is a key criterion for high-grade carcinoma, it is the *combination* of frequent, suprabasal, and atypical mitoses, alongside severe cytologic atypia, that defines it. In a lesion that is otherwise architecturally and cytologically low-grade, isolated atypical mitosis is generally considered sufficient evidence to classify the lesion as a low-grade carcinoma rather than PUNLMP, but insufficient, by itself, to warrant a high-grade diagnosis.\n\n4.  **Necrosis**: The presence of \"focal luminal necrotic debris\" (single-cell necrosis) is more common in carcinomas than in PUNLMP. Crucially, the absence of \"broad zones of tumor (comedo-type) necrosis\" is a strong feature arguing against high-grade carcinoma.\n\n**Conclusion based on WHO/ISUP Criteria:**\nThe lesion exhibits features that are more-than-minimal atypia. The nuclear features (\"mild to moderate\" enlargement, irregular membranes, identifiable nucleoli) and, most decisively, the single atypical mitotic figure, elevate this lesion beyond the criteria for PUNLMP. However, the overall orderly architecture, maintenance of polarity, lack of severe pleomorphism, low mitotic rate, and absence of comedo-necrosis are inconsistent with a diagnosis of high-grade papillary urothelial carcinoma. The constellation of findings—orderly architecture with mild to moderate cytologic atypia and other borderline features—is the epitome of a Low-Grade Papillary Urothelial Carcinoma.\n\n### Option-by-Option Analysis\n\n**A. Urothelial papilloma**\nThis diagnosis requires a lesion with slender, simple papillae lined by urothelium of normal thickness and cytology, indistinguishable from normal urothelium. The described features including \"urothelial thickness of $6$ to $8$ cell layers,\" \"mild to moderate nuclear enlargement,\" hyperchromasia, and an atypical mitosis are all incompatible with this diagnosis.\n**Verdict: Incorrect.**\n\n**B. Papillary urothelial neoplasm of low malignant potential (PUNLMP)**\nPUNLMP is characterized by thicker-than-normal urothelium but with minimal, uniform cytologic atypia (monotonous, enlarged nuclei with smooth contours and inconspicuous nucleoli). Mitoses, if present, are rare, basal, and not atypical. The lesion in this case shows \"moderate\" nuclear enlargement, \"slightly irregular nuclear membranes,\" and, most critically, \"a single atypical mitotic figure.\" These features, particularly the atypical mitosis, represent a degree of atypia that exceeds the threshold for PUNLMP.\n**Verdict: Incorrect.**\n\n**C. Low-grade papillary urothelial carcinoma**\nThis category is defined by orderly papillary architecture with mild to moderate cytologic atypia. This includes variation in nuclear size, hyperchromasia, irregular nuclear contours, and small nucleoli. Mitoses are infrequent and may be scattered. The description in the problem statement aligns perfectly with these criteria. The \"mild to moderate\" cytologic atypia is present. The orderly architecture is retained. The low mitotic rate is consistent. The presence of a single atypical mitosis, while a \"high-grade\" feature in isolation, is the key finding that distinguishes this lesion from PUNLMP and cements the diagnosis of carcinoma, albeit low-grade, given the otherwise non-high-grade background.\n**Verdict: Correct.**\n\n**D. High-grade papillary urothelial carcinoma**\nThis diagnosis requires marked architectural disorder and/or marked (severe) cytologic atypia. Features include loss of polarity, significant nuclear pleomorphism, coarse chromatin, prominent nucleoli, frequent and atypical mitoses, and often comedo-necrosis. The problem explicitly states a lack of these features: \"orderly, tiered nuclear alignment,\" \"largely maintained nuclear polarity,\" \"no marked discohesion, no sheets of highly pleomorphic cells,\" and \"no broad zones of tumor (comedo-type) necrosis.\" The cytologic atypia is only \"mild to moderate,\" not marked.\n**Verdict: Incorrect.**\n\n**E. Carcinoma in situ (CIS)**\nCIS is a flat, non-papillary lesion composed of high-grade malignant cells confined to the urothelium. The problem explicitly states the lesion is \"exophytic papillary\" and that \"there is no flat component resembling carcinoma in situ.\"\n**Verdict: Incorrect.**", "answer": "$$\\boxed{C}$$", "id": "4465022"}, {"introduction": "A pathologist’s diagnosis is only as reliable as the specimen they interpret, and surgical specimens are rarely pristine. This exercise focuses on the critical, real-world skill of identifying common artifacts—such as thermal injury, crush artifact, and retraction spaces—that are frequently encountered in transurethral resections of bladder tumors (TURBT). By learning to distinguish these mimics from true pathological findings like muscle invasion or lymphovascular invasion, you will practice the disciplined approach required to prevent diagnostic errors that could lead to incorrect patient staging and management. [@problem_id:4465002]", "problem": "A transurethral resection of bladder tumor (TURBT) yields fragmented chips of a high-grade urothelial carcinoma. On hematoxylin and eosin sections, several findings raise concern for invasive stage and lymphovascular invasion. At the cauterized edges, tissue shows homogenized eosinophilic stroma with loss of nuclear detail in adjacent smooth muscle bundles, such that the boundary between lamina propria and muscularis propria is difficult to discern. Around several tumor nests there are clear, angular peritumoral clefts without red blood cells or an identifiable endothelial lining. In other foci, cords of tumor are fragmented into streaks with smudged, hyperchromatic nuclei and compressed stroma such that the underlying architecture is poorly preserved. Based on fundamental definitions that invasion requires growth into anatomically defined compartments and that lymphovascular invasion requires tumor within an endothelial-lined vascular space, select the option that correctly identifies the artifacts present and explains how each can confound pathologic staging and lymphovascular invasion assessment, including the most appropriate way to adjudicate the uncertainty in this TURBT specimen.\n\nA. The cauterized edges represent thermal injury that can obliterate smooth muscle detail, making superficially invasive tumor appear to abut or traverse muscle; peritumoral clefts represent retraction artifact that can mimic but do not establish lymphovascular invasion; the nuclear smudging and streaming reflect crush artifact that obscures architectural relationships. The appropriate response is to avoid overcalling depth or lymphovascular invasion in these areas, seek corroboration with endothelial and muscle-specific immunohistochemistry when feasible, examine deeper levels, and recommend re-resection if muscularis propria cannot be confidently evaluated.\n\nB. The peritumoral clefts are diagnostic of lymphovascular invasion because they outline true vascular channels; thermal injury does not materially affect depth assessment; crush artifact predominantly indicates high proliferative activity and supports a higher grade rather than affecting stage.\n\nC. Thermal injury generates true endothelial-lined spaces as tissue retracts from heat, so lymphovascular invasion should be called at cauterized margins; crush artifact reliably pushes tumor into muscle, serving as evidence of muscularis propria invasion; retraction spaces indicate tumor necrosis rather than an artifact.\n\nD. The smudged, hyperchromatic tumor cords are best interpreted as carcinoma in situ, so invasion cannot be assessed; peritumoral clefts define lymphatic spaces and should be reported as lymphatic invasion; thermal artifact is evidence that the tumor has invaded deeply enough to contact the resection loop, which implies invasion of muscularis propria.", "solution": "The user has provided a clinical vignette from the field of surgical pathology and asks for the correct interpretation of several histologic findings and the appropriate course of action.\n\n**Step 1: Extract Givens**\n-   Specimen Type: Transurethral resection of bladder tumor (TURBT) yielding fragmented chips.\n-   Diagnosis: High-grade urothelial carcinoma.\n-   Finding 1: At cauterized edges, there is homogenized eosinophilic stroma with loss of nuclear detail in adjacent smooth muscle bundles.\n-   Consequence 1: The boundary between lamina propria and muscularis propria is difficult to discern.\n-   Finding 2: Around several tumor nests, there are clear, angular peritumoral clefts without red blood cells or an identifiable endothelial lining.\n-   Finding 3: In other foci, cords of tumor are fragmented into streaks with smudged, hyperchromatic nuclei and compressed stroma.\n-   Consequence 3: The underlying architecture is poorly preserved.\n-   Fundamental Definition 1: Invasion requires growth into anatomically defined compartments.\n-   Fundamental Definition 2: Lymphovascular invasion (LVI) requires tumor within an endothelial-lined vascular space.\n-   Question: Identify the artifacts, explain how they confound staging and LVI assessment, and describe the appropriate method to resolve the uncertainty.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is evaluated against the validation criteria.\n\n-   **Scientifically Grounded:** The problem is firmly based on established principles of histopathology. The descriptions of thermal artifact (cautery), crush artifact, and retraction artifact are classic and accurate. The definitions provided for invasion and lymphovascular invasion are the standard definitions used globally in pathology practice (e.g., by the World Health Organization and the College of American Pathologists). The scenario of a fragmented TURBT specimen with these artifacts is a common and realistic diagnostic challenge. The problem is scientifically sound.\n-   **Well-Posed:** The problem presents a specific set of observations and asks for their interpretation and the correct management of the resulting diagnostic uncertainty based on the provided definitions. This structure allows for a unique, correct solution based on standard medical practice.\n-   **Objective:** The language is technical, precise, and descriptive, using standard terminology from the field of pathology (e.g., \"homogenized eosinophilic stroma,\" \"smudged, hyperchromatic nuclei\"). It is free of subjective or ambiguous phrasing.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. It is a well-formulated, scientifically sound question that tests fundamental knowledge in surgical pathology. I will now proceed with the derivation of the solution and evaluation of the options.\n\n**Principle-Based Derivation**\n\nThe problem requires the identification and interpretation of three distinct histopathologic artifacts and their impact on staging a urothelial carcinoma.\n\n1.  **Analysis of Finding 1 (Cauterized Edges):** The description—\"homogenized eosinophilic stroma with loss of nuclear detail\"—is the quintessential presentation of **thermal artifact** caused by the electrocautery instrument used during the TURBT procedure. A critical component of bladder cancer staging is determining if the tumor invades the thick smooth muscle layer of the bladder wall, the muscularis propria. Invasion into this layer defines the tumor as stage $pT2$ or higher, a crucial distinction that often necessitates radical cystectomy. Invasion confined to the connective tissue above the muscle (lamina propria) is stage $pT1$. The problem correctly states that this thermal artifact \"makes the boundary between lamina propria and muscularis propria difficult to discern.\" A pathologist cannot confidently diagnose $pT2$ invasion if the muscle architecture is destroyed by heat. Attempting to do so risks over-staging the tumor, leading to unnecessarily aggressive treatment. Therefore, thermal artifact is a major confounder of pathologic stage assessment.\n\n2.  **Analysis of Finding 2 (Peritumoral Clefts):** The description—\"clear, angular peritumoral clefts without red blood cells or an identifiable endothelial lining\"—is the classic appearance of **retraction artifact**. This artifact arises from the differential shrinkage of tumor nests and the surrounding stroma during tissue processing and fixation, creating artificial spaces. The provided definition of LVI mandates the presence of tumor \"within an endothelial-lined vascular space.\" Since these clefts lack an endothelial lining, they do not meet the criteria for LVI. They are a well-known mimic of LVI and a common diagnostic pitfall. To definitively identify LVI, one must find tumor cells within a space that is unequivocally lined by endothelial cells, often confirmed with immunohistochemical stains for endothelial markers like CD31, CD34, or ERG.\n\n3.  **Analysis of Finding 3 (Streaked Tumor):** The description—\"fragmented into streaks with smudged, hyperchromatic nuclei and compressed stroma\"—is the pathognomonic appearance of **crush artifact**. This occurs when tissue is mechanically compressed, for example, by the surgeon's forceps. This mechanical force distorts cellular and architectural features, smearing the nuclei and obscuring the relationship between the tumor and the stroma. Similar to thermal artifact, crush artifact makes it impossible to reliably assess invasion. A streak of crushed tumor cells juxtaposed with stroma or muscle could be an artifactual displacement rather than true biologic invasion.\n\n**Adjudication of Uncertainty:**\nBased on the above analysis, the proper pathologic practice in the face of these artifacts is one of caution and diligence.\n-   Do not diagnose muscularis propria invasion ($pT2$) in areas obscured by thermal or crush artifact.\n-   Do not diagnose LVI based on retraction artifact.\n-   The pathologist's report must transparently state that staging is uncertain due to these artifacts.\n-   Ancillary studies can be employed. Immunohistochemistry for muscle markers (e.g., desmin, smooth muscle actin) can help identify residual muscularis propria, and endothelial markers (CD31, ERG) can confirm or rule out true LVI.\n-   Examining deeper sections (levels) of the paraffin block may reveal better-preserved areas for assessment.\n-   If the presence and/or invasion status of muscularis propria cannot be determined after exhausting all available tissue and techniques, the standard of care is to recommend a **repeat TURBT**. This is crucial to obtain an adequate sample for accurate staging, which is paramount for guiding patient therapy.\n\n**Option-by-Option Analysis**\n\n**A. The cauterized edges represent thermal injury that can obliterate smooth muscle detail, making superficially invasive tumor appear to abut or traverse muscle; peritumoral clefts represent retraction artifact that can mimic but do not establish lymphovascular invasion; the nuclear smudging and streaming reflect crush artifact that obscures architectural relationships. The appropriate response is to avoid overcalling depth or lymphovascular invasion in these areas, seek corroboration with endothelial and muscle-specific immunohistochemistry when feasible, examine deeper levels, and recommend re-resection if muscularis propria cannot be confidently evaluated.**\nThis option correctly identifies all three artifacts: thermal injury (cautery), retraction artifact, and crush artifact. It accurately describes their respective impact on confounding the assessment of invasion depth (staging) and LVI. Furthermore, it outlines the exact, standard-of-care approach for managing the diagnostic uncertainty: diagnostic caution, use of ancillary stains, examining more tissue, and recommending re-resection if a definitive stage cannot be assigned. This aligns perfectly with the principles derived above.\n**Verdict: Correct**\n\n**B. The peritumoral clefts are diagnostic of lymphovascular invasion because they outline true vascular channels; thermal injury does not materially affect depth assessment; crush artifact predominantly indicates high proliferative activity and supports a higher grade rather than affecting stage.**\nThis option is incorrect on all counts.\n-   It misinterprets retraction clefts as LVI, which contradicts the provided definition (lack of endothelial lining).\n-   It falsely claims thermal injury does not affect depth assessment, when in fact it is a primary confounder.\n-   It incorrectly links crush artifact to proliferative activity; crush artifact is a mechanical distortion with no intrinsic biological meaning regarding proliferation, and its main effect is on assessing architecture and stage.\n**Verdict: Incorrect**\n\n**C. Thermal injury generates true endothelial-lined spaces as tissue retracts from heat, so lymphovascular invasion should be called at cauterized margins; crush artifact reliably pushes tumor into muscle, serving as evidence of muscularis propria invasion; retraction spaces indicate tumor necrosis rather than an artifact.**\nThis option is replete with dangerous falsehoods.\n-   Thermal injury destroys tissue, including endothelium; it does not create new, endothelial-lined spaces.\n-   Using crush artifact as evidence of invasion is a fundamental and serious error in pathology; it is an artifactual displacement, not true invasion.\n-   While necrosis can cause spaces, the classic description provided is for retraction artifact.\n**Verdict: Incorrect**\n\n**D. The smudged, hyperchromatic tumor cords are best interpreted as carcinoma in situ, so invasion cannot be assessed; peritumoral clefts define lymphatic spaces and should be reported as lymphatic invasion; thermal artifact is evidence that the tumor has invaded deeply enough to contact the resection loop, which implies invasion of muscularis propria.**\nThis option demonstrates multiple misconceptions.\n-   It misidentifies crush artifact as carcinoma in situ (CIS). These are distinct entities.\n-   It incorrectly equates retraction clefts with lymphatic invasion.\n-   It makes a faulty logical leap that contact with the cautery loop implies invasion of muscularis propria. A surgeon can resect and cauterize a completely superficial tumor. The presence of cautery only marks the limit of the resection, not a specific anatomic depth.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4465002"}, {"introduction": "In modern medicine, a pathologist’s role extends beyond diagnosis to providing key data for prognostic assessment. This hands-on calculation utilizes the widely accepted European Organisation for Research and Treatment of Cancer (EORTC) risk model for non-muscle-invasive bladder cancer. By inputting the specific pathologic features of a tumor—such as stage, grade, size, and number—you will translate your diagnostic findings into a quantitative prediction of recurrence risk, illustrating how histopathology directly informs clinical decision-making and patient management. [@problem_id:4465032]", "problem": "A non-muscle-invasive urothelial carcinoma of the bladder is commonly managed with transurethral resection of bladder tumor (TURBT) followed by risk-adapted intravesical therapy, and the probability of recurrence can be estimated using the European Organisation for Research and Treatment of Cancer (EORTC) risk tables. As foundational facts, the EORTC recurrence scoring system assigns points based on clinicopathologic features, and maps a total score to empirically derived $1$-year and $5$-year recurrence probabilities. Use this well-tested framework as the base for your calculation.\n\nPoint assignment for recurrence according to EORTC:\n- Number of tumors: $0$ points if $1$ tumor, $3$ points if $2$–$7$ tumors, $6$ points if $\\geq 8$ tumors.\n- Tumor diameter $\\geq 3$ cm: $0$ points if no, $3$ points if yes.\n- Prior recurrence rate: $0$ points if primary tumor, $2$ points if $\\leq 1$ recurrence per year, $4$ points if $>1$ recurrence per year.\n- Pathologic stage: $0$ points if $Ta$, $1$ point if $T1$.\n- Concomitant carcinoma in situ (CIS): $0$ points if absent, $2$ points if present.\n- Histologic grade (World Health Organization $1973$): $0$ points if $G1$, $1$ point if $G2$, $2$ points if $G3$.\n\nMapping from the total recurrence score to $1$-year and $5$-year recurrence probabilities (expressed as decimals):\n- Total score $0$: $1$-year $0.15$, $5$-year $0.31$.\n- Total score $1$–$4$: $1$-year $0.24$, $5$-year $0.46$.\n- Total score $5$–$9$: $1$-year $0.38$, $5$-year $0.62$.\n- Total score $10$–$14$: $1$-year $0.62$, $5$-year $0.78$.\n- Total score $15$–$17$: $1$-year $0.84$, $5$-year $0.90$.\n\nA $68$-year-old patient undergoes TURBT for multifocal non-muscle-invasive urothelial carcinoma. Pathology and clinical history reveal the following:\n- Number of visible tumors: $5$.\n- Largest tumor diameter: $3.5$ cm.\n- Prior recurrence rate: $2$ documented recurrences in the last $12$ months (i.e., $>1$ recurrence per year).\n- Pathologic stage: $T1$.\n- Histologic grade per World Health Organization $1973$: $G2$.\n- Concomitant CIS: none observed.\n\nUsing the foundational EORTC recurrence scoring system and its probability mapping above, calculate the patient’s $1$-year and $5$-year recurrence risks as decimals. Round your final results to three significant figures. Provide your two values in a single row matrix, with the $1$-year risk first and the $5$-year risk second. Do not include any units in your final boxed answer.", "solution": "The problem statement is evaluated as valid. It is scientifically grounded, well-posed, and objective. The provided information is based on the established European Organisation for Research and Treatment of Cancer (EORTC) risk stratification model for non-muscle-invasive urothelial carcinoma, which is a standard clinical tool. All necessary data for the calculation are provided, and there are no internal contradictions or ambiguities. The task is to apply the given scoring rules and probability mapping to a specific patient case.\n\nThe solution proceeds by first calculating the patient's total EORTC recurrence score based on the six specified clinicopathologic features. Subsequently, this total score is used to determine the corresponding $1$-year and $5$-year recurrence probabilities from the provided mapping table.\n\nLet $S$ be the total recurrence score. $S$ is the sum of the points from the six features:\n$S = S_{\\text{num}} + S_{\\text{diam}} + S_{\\text{rate}} + S_{\\text{stage}} + S_{\\text{CIS}} + S_{\\text{grade}}$\n\nThe points for each feature are determined as follows:\n\n1.  **Number of tumors ($S_{\\text{num}}$)**: The patient has $5$ tumors. According to the EORTC criteria, having $2$–$7$ tumors corresponds to $3$ points.\n    $$S_{\\text{num}} = 3$$\n\n2.  **Tumor diameter ($S_{\\text{diam}}$)**: The largest tumor diameter is $3.5$ cm, which is greater than or equal to $3$ cm. This condition corresponds to $3$ points.\n    $$S_{\\text{diam}} = 3$$\n\n3.  **Prior recurrence rate ($S_{\\text{rate}}$)**: The patient's history includes $2$ recurrences in the last $12$ months. This rate is greater than $1$ recurrence per year. This condition corresponds to $4$ points.\n    $$S_{\\text{rate}} = 4$$\n\n4.  **Pathologic stage ($S_{\\text{stage}}$)**: The pathologic stage is $T1$. This corresponds to $1$ point.\n    $$S_{\\text{stage}} = 1$$\n\n5.  **Concomitant carcinoma in situ ($S_{\\text{CIS}}$)**: Carcinoma in situ (CIS) is absent (\"none observed\"). This corresponds to $0$ points.\n    $$S_{\\text{CIS}} = 0$$\n\n6.  **Histologic grade ($S_{\\text{grade}}$)**: The histologic grade is $G2$ (WHO $1973$). This corresponds to $1$ point.\n    $$S_{\\text{grade}} = 1$$\n\nNow, the total recurrence score $S$ is calculated by summing the points from each category:\n$$S = 3 + 3 + 4 + 1 + 0 + 1 = 12$$\nThe total score for this patient is $12$.\n\nNext, we use the provided mapping table to find the $1$-year and $5$-year recurrence probabilities associated with this score. The patient's score of $12$ falls within the range of $10$–$14$.\n\n-   For a total score of $10$–$14$, the $1$-year recurrence probability is $0.62$.\n-   For a total score of $10$–$14$, the $5$-year recurrence probability is $0.78$.\n\nThe problem requires the final results to be rounded to three significant figures. The values from the table are $0.62$ and $0.78$. To express these to three significant figures, we add a trailing zero.\n\n-   $1$-year recurrence risk: $0.620$\n-   $5$-year recurrence risk: $0.780$\n\nThe final answer is to be provided as a single row matrix with the $1$-year risk first, followed by the $5$-year risk.", "answer": "$$\\boxed{\\begin{pmatrix} 0.620 & 0.780 \\end{pmatrix}}$$", "id": "4465032"}]}